GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (NAS:CNTA) » Definitions » Price-to-Free-Cash-Flow

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-05-23), Centessa Pharmaceuticals's share price is $8.35. Centessa Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.54. Hence, Centessa Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Centessa Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

CNTA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.86
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Centessa Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.37. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.54.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -123.20% per year.

During the past 5 years, Centessa Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was -123.20% per year. The lowest was -197.50% per year. And the median was -160.35% per year.


Centessa Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Centessa Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Price-to-Free-Cash-Flow Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Centessa Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Centessa Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Centessa Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Centessa Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=8.35/-1.54
=N/A

Centessa Pharmaceuticals's Share Price of today is $8.35.
Centessa Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.54.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Centessa Pharmaceuticals  (NAS:CNTA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Centessa Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals (Centessa Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Executives
Harris Rotman officer: SVP Regulatory Affairs C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Antoine Yver officer: Chief Medical Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Tia L Bush officer: Chief Quality Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Karen M. Anderson officer: Chief People Officer C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421
David J Grainger officer: Chief Innovation Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Gregory M Weinhoff officer: Chief Financial Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Thomas Templeman officer: Chief Technology Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
David M Chao officer: Chief Administrative Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Iqbal J Hussain officer: General Counsel C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Mathias Hukkelhoven director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Saurabh Saha director, officer: Chief Executive Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Javad Shahidi officer: Chief Medical Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Medicxi Ventures Management (jersey) Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Rubertis Francesco De director C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204
Aaron Kantoff director C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Headlines

From GuruFocus